Phlogosis and atherosclerosis;Flogosi e aterosclerosi

Recenti Progressi in Medicina

Volumn 95, Issue 3, 2004, Pages 153-156

  Zazzaro, Bernardino ^a,b  

^a Osp Umberto I   (Italy)

^b NONE   (Italy)

Author keywords

Acute inflammation's proteins; Reactive oxygene species; Statins; Toll like receptors

Indexed keywords

LIPOPROTEIN; REACTIVE OXYGEN METABOLITE; SCAVENGER RECEPTOR; STATIN; TOLL LIKE RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; HUMAN; IMMUNITY; INFECTION; INFLAMMATION; MACROPHAGE ACTIVATION; PHLOGOSIS; PROTEIN ANALYSIS; REVIEW;

ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; HUMANS; INFLAMMATION; MEMBRANE GLYCOPROTEINS; PROTEIN C; REACTIVE OXYGEN SPECIES; RECEPTORS, CELL SURFACE; RISK FACTORS; TOLL-LIKE RECEPTORS;

EID: 2342544763     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Witzum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344: 793-5.
2. Witzum JL. Role of oxidised low density lipoprotein in atherogenesis. Br Heart J 1993; 69 (S12): 518.
3. Dotevall A, Hulthe J, Rosengren A, Wiklund O, Wilhelmsen L. Autoantibodies against oxidized low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women. Clin Sci (Lond) 2001; 101: 523-31.
4. Seifert PS, Hugo F, Hansson GK, Bhakdi S. Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol acumulation in the aortic intima of hypercolesterolemic rabbits. Lab Invest 1989; 60: 747-52.
5. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883-7.
6. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrofage: implication for cholesterol deposition in atherosclerosis. Ann Rev Biochem 1983; 52: 223-61.
7. Brown MS, Goldstein JL. Scavengig for receptors. Nature 1990; 343: 508-9.
8. Mehta JL, Li D. Identification and autoregolation of receptor for OX-LDL in cultured human coronary artery endothelial cells. Biochem Biophis Res Commun 1998; 248: 511-4.
9. Klouche M, Rose-John S, Schmiedt W, Bhakdi S. Enzimatically degraded, nonoxidized LDL induces human vascular smooth muscle cell activation, foam cell transformation, and proliferation. Circulation 2000; 101: 1799-805.
10. Libby P, Clinton SK. The role of macrophages in atherogenesis. Curr Opin Lipidol 1993; 4: 355-63.
11. Lorant D, Patel KD, Mc Intyre TM, et al. Coexpression of GMP-140 and PAF by endothelium stimulated by histamine or thrombine: a juxtacrine system for adhesion and activation of neutrophils. J Cell Biol 1991; 115: 223-34.
12. Mazzone A, Pasotti D, Mazzucchelli I, Fossati G, Ricevuti G. Ruolo dei granulociti nella cardiopatia ischemica. Recenti Prog Med 1994; 85: 397-406.
13. Cha-Molstad H, Agraval A, Zhang D, Samols D, Kuscner I. The Rel family member P50 mediates cytokine-induced C-reactive protein expression by a novel mechanism. J Immunol 2000; 165: 4592-7.
14. Westhuyzen J, Healy H. Biology and relevance of C-reactive protein in cardiovascular and renal disease. Ann Clin Lab Sci 2000; 30: 133-43.
15. Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure Fold Des 1999; 7: 169-77.
16. Sorensen IJ, Andersen O, Nielsen EH, Svehag SE. Native human serum amyloid P component is a single pentamer. Scand J Immunol 1995; 41: 263-7.
17. Pepys MB, Hirschfield GM. C-reactive protein and atherothrombosis. Ital Heart J 2001; 2: 196-9.
18. Yasojjima K, Schwab C, Mc Geer EG, Mc Geer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001; 158: 1039-51.
19. Szalai AJ, Agraval A, Greenhough TJ, Volanakis JE. C-reactive protein: structural biology and defense function. Clin Chem Lab Med 1999; 37: 265-70.
20. Potempa LA, Siegel JN, Fiedel BA, Potempa RT, Gewurz H. Expression, detection and assay of neoantigen (Neo-CRP) associated with a free, human C-reactive protein subunit. Mol Immunol 1987; 24: 531-41.
21. Agrawal A, Volanakis JE. Probing the C1q-binding site on human C-reactive protein directed mutagenesis. J Immunol 1994; 11: 5404-10.
22. Agraval A, Simpson MJ, Black S, Carey M, Samols D. A C-reactive protein mutant that does not bind to phosphocoline and pneumococcal C-polysaccharide. J Immunol 2002; 169: 217-22.
23. Agraval A, Shrive AK, Greenhough TJ, Volanakis JE. Topology and structure of the C1q-binding site on C reactive protein. J Immunol 2001; 166: 3998-4004.
24. Hundt M, Zielinska-Skowronek M, Schmidt RE. Lack of specific receptors for C reactive protein on white basal cells. Eur J Immunol 2001; 31: 3475-83.
25. Bhakdi S, Torzewski M, Klouche M, Hemmes M. Complement and atherogenesis: binding of CRP to degraded LDL enhances complement activation. Arterioscler Thromb Vasc Biol 1999; 19: 2348-54.
26. O'Malley T, Ludlam CA, Riemermsa RA, Fox KA. Early increase in levels of soluble inter-cellular adhesion molecule-1 (s ICAM-1); potential risk factor for acute coronary syndromes. Eur Heart J 2001; 22: 1226-34.
27. Kluft C, de Maat MP. Determination of abitual low of C-reactive protein in individuals. Ital Heart J 2001; 2: 172-80.
28. de Maat MP, Kluft C. Determinants of C-reactive protein concentrantion in blood. Ital Heart J 2001; 2: 189-95.
29. Pankow JS, Folsom AR, Cushman M, Borecki IB, Hopkins PN. Familial and genetic determinants of systemic markers of inflammation: the NHLBI family hearth study. Atherosclerosis 2001; 154: 681-9.
30. Zazzaro B, Pietroiusti A, Luzzi I, Fontana C. Atorvastatine influence on acute inflammation parameters. Nutr Metab Cardiovasc Dis 2002; 12: 231.
31. Cambau E. C-reactive protein: general review and role in the study of infection. Pathol Biol (Paris) 1988; 36: 1232-6.
32. Means TK, Golenbock DT, Fenton MJ. Structure and function of Toll-like receptor proteins. Life Sci 200; 68: 241-58.
33. Akira S, Yamamoto M, Takeda K. Role of adapters in Toll-like receptor signalling. Biochem Soc Trans 2003; 31: 637-42.
34. Suzuki N, Suzuki S, Yeh WC. IRAK-4 as the central TIR signalling mediator in innate immunity. Trends Immunol 2002; 23: 503-6.
35. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of Toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation . Circulation 2002; 105: 1158-61.
36. Vink A, Schoneveld AH, van der Meer JJ, van Middelaar BJ, et al. In vivo evidence for a role of Toll-like receptor 4 in the development intimal lesions. Circulation 2002; 106: 1985-90.
37. Xu XH, Shah PK, Faure E, Equils O, Thomas L, et al. Toll-like receptor-4 is expressed by macrophages in murine and hurolipid -rich atherosclerotic plaques and up regulation by oxidized LDL. Circulation 2001; 104: 103-8.
38. Frantz S, Kelly RA, Bourcier T. Role of TLR-2 in the activation of nuclear kappa B by oxidation stress in cardiac myocites. J Biol Chem 2001; 276: 5197-203.
39. Ishida I, Kubo H, Suzuki S, Suzuki T, Akashi S, Inoue K et al. Hypoxia diminishes toll-like receptor 4 expression through reactive oxigen species generated by mitochondria in endothelial cells. Immunol 2002; 169: 2069-75.
40. Aliprantis AO, Weiss DS, Zychlinsky A. Toll-like receptor-2 transduces signals for NF-kappa B activation, apoptosis and reactive oxygen species production. J Endotoxin Res 2001; 7: 287-91.
41. Vasselon T, Hanlon WA, Wright SD, Detmers PA. Toll-like receptor 2 (TLR2) mediates activation of stress activated MAPkinase p38. J Leukoc Biol 2002; 71: 503-10.
42. Liao W, Rudling M, Angelin B. Endotoxin suppress mouse hepatic low-density lipoprotein receptor expression via pathway independent of the toll-like receptor 4. Hepatology 1999; 30: 1252-6.
43. Hwang D. Modulation of the expression of cyclooxygenase-2 by fatty acids mediated through toll-like receptor 4 derived signalling pathways. FASEB J 2001; 15: 2556-64.
44. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, et al. Toll-like recptor 4 polymorphism and atherogenesis. NEJM 2002; 347: 185-92.
45. Miller YI, Viriyakosol S, Binder CJ, Feramisco JR, et al. Minimally modified LDL binds to CD 14, induces macrophage spread via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem 2003; 278: 1561-8.